Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 93,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "f4c9d43d-c77b-4366-8211-57735fb86f9e",
"title": "Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript",
"description": "Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma July 22, 2026 8:30 AM EDTCompany ParticipantsDiantha...",
"keywords": "",
"snippet": "Presentation\n\nGood morning, and welcome to Curis' Emavusertib Update Call. [Operator Instructions] Please note this event is being recorded. And I would now lik...",
"url": "https://seekingalpha.com/article/4924335-curis-inc-cris-discusses-positive-data-from-emavusertib-combination-study-in-primary-cns",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2026-07-22T17:50:25.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CRIS",
"name": "Curis, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 85.62407,
"sentiment_score": 0.796267,
"highlights": [
{
"highlight": "Presentation\n\nGood morning, and welcome [+244 characters]",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Diantha Duvall\n\nCFO and Principal Financ[+287 characters]",
"sentiment": 0.9313,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Curis</em>, <em>Inc</em>. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "905e5996-d507-4f81-9490-0134e8d39f4a",
"title": "Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy",
"description": "Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and financial improvements. Read more on FBIO stock here.",
"keywords": "",
"snippet": "Fortress Biotech, Inc. ( FBIO ) may not be a low-risk biotech player, but currently it looks undervalued when compared to its current assets, cash position, and...",
"url": "https://seekingalpha.com/article/4924312-fortress-biotech-stock-cash-above-market-cap-and-royalty-upside-speculative-buy",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252173407/image_2252173407.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2026-07-22T17:50:18.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "FBIO",
"name": "Fortress Biotech, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 75.15692,
"sentiment_score": 0.1822,
"highlights": [
{
"highlight": "<em>Fortress</em> <em>Biotech</em>, <em>[+184 characters]",
"sentiment": 0.2617,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Fortress</em> <em>Biotech</em>: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy",
"sentiment": 0.1027,
"highlighted_in": "title"
}
]
},
{
"symbol": "FBIOP",
"name": "Fortress Biotech, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 75.15692,
"sentiment_score": 0.1822,
"highlights": [
{
"highlight": "<em>Fortress</em> <em>Biotech</em>, <em>[+184 characters]",
"sentiment": 0.2617,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Fortress</em> <em>Biotech</em>: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy",
"sentiment": 0.1027,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0cc6d1e9-fc4b-4399-b524-5b575bde3f39",
"title": "Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (NASDAQ:ARWR)",
"description": "Arrowhead Pharmaceuticals, Inc. jumped on Phase 3 plozasiran sHTG data; see key catalysts, risks, and upside vs Ionis ahead of filings. Click for this ARWR update.",
"keywords": "",
"snippet": "If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...",
"url": "https://seekingalpha.com/article/4924293-arrowhead-stock-up-on-shtg-data-no-ceiling-on-valuation-growth-potential",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2274129795/image_2274129795.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2026-07-22T17:28:45.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARWR",
"name": "Arrowhead Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 78.48126,
"sentiment_score": 0.3812,
"highlights": [
{
"highlight": "The stock of <em>Arrowhead</em> <em>Phar[+256 characters]",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (<em>NASDAQ:ARWR</em>)",
"sentiment": 0.1027,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "15effa42-0ff9-4a8c-b014-0be49d635ef2",
"title": "Arrowhead Pharma Stock Jumps 24% On Positive Phase 3 Plozasiran Trial Results",
"description": "Arrowhead Pharmaceuticals, Inc. (ARWR) shares surged $17.98, or 24.13 percent, to $92.50 on Wednesday, after the company reported positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4 studies evaluating plozasiran in patients with severe hypertriglyceridemia.",
"keywords": "Stock Jumps, Arrowhead Pharmaceuticals, Inc., Positive Phase, Plozasiran Trial Results",
"snippet": "Arrowhead Pharmaceuticals, Inc. (ARWR) shares surged $17.98, or 24.13 percent, to $92.50 on Wednesday, after the company reported positive topline results from ...",
"url": "https://www.rttnews.com/story.aspx?Id=3669396",
"image_url": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
"language": "en",
"published_at": "2026-07-22T14:50:30.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARWR",
"name": "Arrowhead Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 47.427246,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "<em>Arrowhead</em> <em>Pharmaceuticals</[+264 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0HI3.L",
"name": "Arrowhead Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 47.429214,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "<em>Arrowhead</em> <em>Pharmaceuticals</[+264 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "ae38fb99-029c-45e7-af76-7a01f3da24d0",
"title": "Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR)",
"description": "Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions. Click here to read an analysis of ARWR stock now.",
"keywords": "",
"snippet": "I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signi...",
"url": "https://seekingalpha.com/article/4924159-arrowhead-pharmaceuticals-redemplo-meets-high-expectations-in-shtg-trials",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/962267088/image_962267088.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2026-07-22T14:24:46.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARWR",
"name": "Arrowhead Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 107.18515,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Arrowhead</em> <em>Pharmaceuticals</em>: Redemplo Meets High Expectations In SHTG Trials (<em>NASDAQ:ARWR</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "6544322c-e39f-4a22-ac11-14b0979413c8",
"title": "Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva",
"description": "Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]",
"keywords": "Alison Silva, Chief Executive Officer, Co-founder Christer Rosén, JUNS, Chief Operations Officer, Neurosciences, Parkinson’s disease, Executive Vice President, The company, Pharmaceuticals, Fireside Chat",
"snippet": "Watch Fireside Chat Below, or Click HERE:\n\nIPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and...",
"url": "https://finance.yahoo.com/healthcare/articles/psychedelic-therapy-meets-m-fireside-172512331.html",
"image_url": "https://s.yimg.com/lo/mysterio/api/08B65497AFBA320D6C70A7AE08BF5B208FC6AFA13BA9347BECFE5634BEE6650D/subgraphmysterio/resizefill_w1200_h800;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fipo_edge_com_346%2Fb2c49da4ad5be30db415a612c16865fa",
"language": "en",
"published_at": "2026-07-22T17:25:12.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "SYBX",
"name": "Synlogic, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 35.781567,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Previously, she was a co‐founder, Exec[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "3f303280-4270-4117-ad6f-d12608cec6f2",
"title": "Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript",
"description": "Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation July 21, 2026 4:30 PM EDTCompany...",
"keywords": "",
"snippet": "Presentation\n\nThank you for standing by, and welcome to Celldex's Phase II PN Data Call. [Operator Instructions] I would now like to hand the call over to Sarah...",
"url": "https://seekingalpha.com/article/4924329-celldex-therapeutics-inc-cldx-discusses-phase-ii-barzolvolimab-results-in-prurigo-nodularis",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2026-07-22T17:10:52.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLDX",
"name": "Celldex Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 122.5687,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Celldex</em> <em>Therapeutics</em>, <em>Inc</em>. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "5d5b18c2-8e92-4e1e-ae9d-9cf67ba82583",
"title": "Oscar Health: Strong Numbers Forced Re-Rating, Now Pay Attention To Continuous Execution",
"description": "Oscar Health has rerated to the $30 range, reflecting its strong performance but reduced asymmetry versus prior opportunities. Learn more about OSCR stock here.",
"keywords": "",
"snippet": "Readers who have followed me would know I have covered Oscar Health, Inc. ( OSCR ) for a while already, since it was in the low teens. In my last analysis\n\nFirs...",
"url": "https://seekingalpha.com/article/4924264-oscar-health-strong-numbers-now-pay-attention-to-continuous-execution",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1860531124/image_1860531124.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2026-07-22T16:40:04.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "OSCR",
"name": "Oscar Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 70.446976,
"sentiment_score": 0.0511,
"highlights": [
{
"highlight": "Readers who have followed me would know [+278 characters]",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Oscar</em> <em>Health</em>: Strong Numbers Forced Re-Rating, Now Pay Attention To Continuous Execution",
"sentiment": -0.0258,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "8a722c25-c6c4-4419-82df-325fd387e26a",
"title": "Intuitive Surgical down as J&J wins FDA nod for surgical robot",
"description": "Johnson & Johnson (JNJ) stock gains as FDA clears the company's Ottava surgical robot, pressuring rivals Intuitive Surgical (ISRG) and Medtronic (MDT). Read more here.",
"keywords": "",
"snippet": "Johnson & Johnson (JNJ) on Wednesday announced the FDA authorization for its Ottava surgical robot, marking its entry into the U.S. robotic soft-tissue surgery ...",
"url": "https://seekingalpha.com/news/4616752-intuitive-surgical-down-jj-wins-fda-nod-surgical-robot",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222831149/image_2222831149.jpg?io=getty-c-w630",
"language": "en",
"published_at": "2026-07-22T16:23:44.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 33.525246,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Johnson</em> & <em>Johnson</em> (JNJ[+248 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ba1cc8a9-9e1e-40f6-8f71-9ed801c5c6ec",
"title": "Vivasor Appoints JP3E Development Corp. (JP 3E Holdings, Inc. (JPTE) Majority Owned Subsidiary) as Exclusive Strategic Representative in the Republic of Korea",
"description": "Strategic Partnership to Accelerate Korean Market Entry, Business Development, and Long-Term Value Creation Across Vivasor's $100 Billion Pipeline of Clinical-Stage Biopharmaceutical Assets",
"keywords": "Vivasor, Appoints, JP3E, Development, Corp., (JP, 3E, Holdings, , Inc., (JPTE), Majority, Owned, Subsidiary), as, Exclusive, Strategic, Representative, in, the, Republic, of, Korea",
"snippet": "Strategic Partnership to Accelerate Korean Market Entry, Business Development, and Long-Term Value Creation Across Vivasor's $100 Billion Pipeline of Clinical-S...",
"url": "https://www.manilatimes.net/2026/07/23/tmt-newswire/globenewswire/vivasor-appoints-jp3e-development-corp-jp-3e-holdings-inc-jpte-majority-owned-subsidiary-as-exclusive-strategic-representative-in-the-republic-of-korea/2389633",
"image_url": "https://manilatimes.net/manilatimes/uploads/images/2026/07/23/1147342.png",
"language": "en",
"published_at": "2026-07-22T16:22:30.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "NVSEF",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.071156,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Vivasor's leadership team includes exper[+319 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "cf36cf8a-b147-4cc7-a90d-b8344c3b5646",
"title": "OKYO Pharma Announces Purchase of Shares by Chairman",
"description": "LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.",
"keywords": "OKYO, Pharma, Announces, Purchase, of, Shares, by, Chairman",
"snippet": "LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational...",
"url": "https://www.manilatimes.net/2026/07/23/tmt-newswire/globenewswire/okyo-pharma-announces-purchase-of-shares-by-chairman/2389626",
"image_url": "https://manilatimes.net/manilatimes/uploads/images/2026/07/23/1147330.jpg",
"language": "en",
"published_at": "2026-07-22T16:21:33.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "EMMLF",
"name": "OKYO Pharma Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 112.05411,
"sentiment_score": 0.087225,
"highlights": [
{
"highlight": "LONDON and NEW YORK, July 22, 2026 (GLOB[+283 characters]",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About OKYOPharma\n\n<em>OKYO</em> <em>Phar[+274 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "For further inquiries:\n\nGet the latest n[+329 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>OKYO</em> <em>Pharma</em> Announces Purchase of Shares by Chairman",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "YI",
"name": "111, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.943157,
"sentiment_score": 0.3182,
"highlights": [
{
"highlight": "OKYO plans to initiate a global Phase 3 [+233 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "OKYO.L",
"name": "OKYO Pharma Limited",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 112.001144,
"sentiment_score": 0.087225,
"highlights": [
{
"highlight": "LONDON and NEW YORK, July 22, 2026 (GLOB[+283 characters]",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "About OKYOPharma\n\n<em>OKYO</em> <em>Phar[+274 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "For further inquiries:\n\nGet the latest n[+329 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>OKYO</em> <em>Pharma</em> Announces Purchase of Shares by Chairman",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "70b42725-c914-4b24-8d63-51d664f4ec0b",
"title": "OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director",
"description": "LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.",
"keywords": "OKYO, Pharma, Announces, Purchase, of, Shares, by, Chief, Development, Officer, and, Director",
"snippet": "LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational...",
"url": "https://www.manilatimes.net/2026/07/22/tmt-newswire/globenewswire/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director/2389536",
"image_url": "https://manilatimes.net/manilatimes/uploads/images/2026/07/22/1147187.jpg",
"language": "en",
"published_at": "2026-07-22T14:19:57.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "YI",
"name": "111, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.319454,
"sentiment_score": 0.3182,
"highlights": [
{
"highlight": "OKYO plans to initiate a global Phase 3 [+233 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "EMMLF",
"name": "OKYO Pharma Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.289474,
"sentiment_score": 0.22412,
"highlights": [
{
"highlight": "LONDON and NEW YORK, July 22, 2026 (GLOB[+273 characters]",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Jacob, PhD, Chief Development Officer an[+217 characters]",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "About OKYOPharma\n\n<em>OKYO</em> <em>Phar[+274 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "For further inquiries:\n\nGet the latest n[+329 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>OKYO</em> <em>Pharma</em> Announces Purchase of Shares by Chief Development Officer and Director",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
},
{
"symbol": "OKYO.L",
"name": "OKYO Pharma Limited",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.23748,
"sentiment_score": 0.22412,
"highlights": [
{
"highlight": "LONDON and NEW YORK, July 22, 2026 (GLOB[+273 characters]",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Jacob, PhD, Chief Development Officer an[+217 characters]",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "About OKYOPharma\n\n<em>OKYO</em> <em>Phar[+274 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "For further inquiries:\n\nGet the latest n[+329 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>OKYO</em> <em>Pharma</em> Announces Purchase of Shares by Chief Development Officer and Director",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "648d1c89-e05c-45b9-a8a5-39740730bfaf",
"title": "Wed: Insurance sector leads gains",
"description": "Enlight, Elbit and the insurance sector led a second day of strong gains. The market will be closed tomorrow for Tisha B’Av.",
"keywords": "",
"snippet": "The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 0.80% to 4,227 points, the Tel Aviv 125 Index rose 0.67% to 4,156.91 points; and the BlueTech...",
"url": "https://en.globes.co.il/en/article-wed-insurance-sector-leads-gains-1001550213",
"image_url": "https://images.globes.co.il/images/NewGlobes/big_image_800/2018/Globes_Archive_800x392.2018729T150619.jpg",
"language": "en",
"published_at": "2026-07-22T16:12:24.000000Z",
"source": "en.globes.co.il",
"relevance_score": null,
"entities": [
{
"symbol": "TEVA",
"name": "Teva Pharmaceutical Industries Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 47.932808,
"sentiment_score": 0.7456,
"highlights": [
{
"highlight": "Nice (Nasdaq: NICE; TASE:NICE) fell 6.31[+316 characters]",
"sentiment": 0.7456,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 180,
"sentiment_avg": 0.27833823934197427
}
]
}
Other details
Entity count
- 11,338